Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...

Sanofi SNY and its partner Regeneron Pharmaceuticals REGN announced that the European Commission (EC) has approved the ...

KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 8 Best Debt Free Stocks to Buy Right Now. On March 24, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Sanofi (SNY) announced that ...

In March 2026, Sanofi reported a series of regulatory and clinical milestones that deepen its immunology footprint and expand its geographic reach. The most advanced of these is Dupixent, a monoclonal ...

Donna Culton, MD, University of North Carolina at Chapel Hill, outlines diagnosing autoimmune blistering diseases. Persistent, intensely itchy rashes in older adults are often written off as eczema or ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Dublin, Oct. 06, 2025 (GLOBE NEWSWIRE) -- The "Bullous Pemphigoid Market - A Global and Regional Analysis: Focus on Therapy Type and Region - Analysis and Forecast, 2025-2035" report has been added to ...

DEAR DR. ROACH: I am a 73-year-old woman who is in otherwise good health, but I was diagnosed with bullous pemphigoid, a rare autoimmune disease, in January 2022. I have been treated by three ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid. The approval is based on results from the pivotal ADEPT phase 2/3 ...